Study sponsor: Dexcom
Drug: Dexcom G7 GCM (continuous glucose monitoring wearable device) in conjunction with Tirzepatide (Tur-zep-e-tide) injections.
Indication: Obesity/Weight Loss
Duration: 52 weeks (about 12 months) – Total compensation up to $600

Inclusions

• Must be ≥ 18 years of age and medically stable.
• BMI must be ≥ 30.
• A1C must be ≤ 6.5.
• GFR value ≥ 15.
• Ability to speak, read, and write in English.
• FEMALE SUBJECTS – IUD or IMPLANT are the ONLY exceptional forms of birth control.

Exclusions

• Diagnosed with Diabetes
• Continuous use of medications regulating glucose levels.
• Unstable/uncontrolled thyroid disorders and high blood pressure.
• Hx of Liver disease
• Diagnosed/Suspension of Cardiac Disease/Congestive Heart Failure.
• Diagnosed with Cancer and malignant within the past 5 years.